CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
B 细胞急性淋巴细胞白血病在 CAR-T 细胞治疗后复发的机制及可能的未来策略
英文原题：The mechanisms of B-cell acute lymphoblastic leukemia relapsing following chimeric antigen receptor-T cell therapy; the plausible future strategies.
查看英文原题
The mechanisms of B-cell acute lymphoblastic leukemia relapsing following chimeric antigen receptor-T cell therapy; the plausible future strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
研究表明，B细胞急性淋巴细胞白血病（B-ALL）具有较高的死亡率和发病负担。研究人员已开发多种治疗策略应对这一疾病。近期开发的嵌合抗原受体（CAR）T细胞能够不依赖主要组织相容性复合体（MHC）识别抗原，并具有更强的活化程度和更持久的效应。然而，已有多例B-ALL复发病例报告。本文旨在汇总近期有关B-ALL相关淋巴细胞逃避CAR-T 细胞机制及可能解决方案的信息。
展开英文摘要原文
Research has demonstrated the high mortality and morbidity associated with B-Acute lymphoblastic lymphoma (B-ALL). Researchers have developed several therapeutic approaches to combat the disorder. Recently, researchers developed chimeric antigen receptors (CARs)-T cells, which recognize antigens independently of major histocompatibility complexes (MHCs) and activate at a higher level with additional persistence.
However, relapsing B-ALL has been reported in several cases. This review article was aimed to collecting recent information regarding the mechanisms used by B-ALL-related lymphocytes to escape from CAR-T cells and the plausible resolution projects.
论文信息
- 作者
- Karimi-Googheri M、Gholipourmalekabadi M、Madjd Z、Shabani Z、Rostami Z、Kazemi Arababadi M、Kiani J
- 第一作者单位
- Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.Iran
- 通讯作者单位
- Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran. Ja.kiani@gmail.com.Iran
- 文献类型
- 综述
- 期刊
- Molecular biology reports2024 Nov 8
- 原文标识
- PubMed 39514017 · DOI 10.1007/s11033-024-10061-2